Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.

Doyle C, Lohmann AE, Iqbal N, Henning JW, Kulkarni S, Califaretti N, Hilton J, Ferrario C, Bouganim N, Mates M, Guillemette S, Leite R, Caron MA, Thireau F, Machado A, Chia S

Open source

DOI: 10.1007/s10549-026-07934-4
Published: 2026 Mar 19
Container: Breast cancer research and treatment
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10549-026-07934-4,
  title = {Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.},
  author = {Doyle C and Lohmann AE and Iqbal N and Henning JW and Kulkarni S and Califaretti N and Hilton J and Ferrario C and Bouganim N and Mates M and Guillemette S and Leite R and Caron MA and Thireau F and Machado A and Chia S},
  year = {2026},
  journal = {Breast cancer research and treatment},
  doi = {10.1007/s10549-026-07934-4},
  url = {https://doi.org/10.1007/s10549-026-07934-4}
}

RIS

TY  - JOUR
TI  - Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.
AU  - Doyle C
AU  - Lohmann AE
AU  - Iqbal N
AU  - Henning JW
AU  - Kulkarni S
AU  - Califaretti N
AU  - Hilton J
AU  - Ferrario C
AU  - Bouganim N
AU  - Mates M
AU  - Guillemette S
AU  - Leite R
AU  - Caron MA
AU  - Thireau F
AU  - Machado A
AU  - Chia S
PY  - 2026
JO  - Breast cancer research and treatment
DO  - 10.1007/s10549-026-07934-4
UR  - https://doi.org/10.1007/s10549-026-07934-4
ER  -

APA

C, D., AE, L., N, I., JW, H., S, K., N, C., J, H., C, F., N, B., M, M., S, G., R, L., MA, C., F, T., A, M., & S, C. (2026). Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.. Breast cancer research and treatment. https://doi.org/10.1007/s10549-026-07934-4

Source records

pubmed · retrieved 2026-09-26T19:37:52.204Z